CardioComm Solutions (
TSX: V.EKG,
Forum) maintained its domestic market potential when the company announced today that Canada’s largest retail pharmacy chains, Rexall and Shoppers Drug Mart, have renewed their listing for the over-the-counter sales of the HeartCheck™ ECG PEN in select locations for 2016.
According to the news release, the number of pharmacies that have received HeartCheck™ ECG PEN orders in 2016 has increased from 647 pharmacies to over 850 locations across the country. The company also continues to supply inventory to independently operated and privately owned pharmacies.
The device has passed regulatory reviews by both Health Canada and the US Food and Drug Administration as the only ECG displaying personal heart monitoring device approved for sale directly to consumers without a physician’s prescription or guidance.
CardioComm continues to fill monthly orders and physicians are now beginning to prescribe the HeartCheck™ ECG PEN to patients. The company will continue to provide updates on the HeartCheck™ Program and participating pharmacy locations at
https://www.theheartcheck.com.
CardioComm Solutions was in the news recently when
the North York, Ontario-based company announced inking a transformative sales and marketing agreement almost a week ago.
Currently there are 114.7m outstanding shares with a market cap of $4.6 million.
FULL DISCLOSURE: CardioComm Solutions is a Stockhouse Publishing client.